Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Diabetes Care Publish Ahead of Print published online ahead of print August 8, 2007
DOI: 10.2337/dc07-1144
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-1144v1
30/11/2804    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vuksan, V.
Right arrow Articles by Hanna, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vuksan, V.
Right arrow Articles by Hanna, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Supplementation of Conventional Therapy with the Novel Grain Salba (Salvia hispanica L.) Improves Major and Emerging Cardiovascular Risk Factors in Type 2 Diabetes: Results of a Randomized Controlled Trial

Vladimir Vuksan, PHD1,,2,,3, Dana Whitham, MSC, RD2,,3, John L Sievenpiper, PHD1,,2, Alexandra L Jenkins, RD, PHD1, Alexander L Rogovik, MD, PHD1, Richard P Bazinet, PHD2, Edward Vidgen, BSC2 and Amir Hanna, MD, FRCPC3

1Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Canada
2Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada
3Department of Medicine, St. Michael's Hospital, Faculty of Medicine, University of Toronto, Toronto, Canada

v.vuksan{at}utoronto.ca

ABSTRACT

Objective:To determine whether addition of Salba (Salvia hispanica L.), a novel whole-grain, rich in fiber, alpha-linolenic acid (ALA) and minerals, to conventional treatment is associated with improvement in major and emerging cardiovascular risk factors in individuals with type 2 diabetes.

Research Design and Methods:Using a single-blind, crossover design, subjects were randomly assigned to receive either 37±4 g/day of Salba or wheat bran for 12 weeks while maintained on their conventional diabetes therapies. Twenty well-controlled subjects with type 2 diabetes (11M:9F; age 64±8 years; BMI 28±4 kg/m2; A1C6.8±0.9%) completed the study. Setting: outpatient clinic (Risk Factor Modification Center, St. Michael's Hospital, Toronto, Canada).

Results:Compared to control, Salba reduced systolic blood pressure (SBP) by 6.3±4 mmHg (p<0.001), hs-CRP (mg/L) by 40±1.6% (p=0.04), and vonWillebrand factor (vWF) by 21±0.3% (p=0.03), with significant decreases in A1C and fibrinogen in relation to the Salba baseline but not with control. There were no changes in safety parameters including liver, kidney and haemostatic function or body weight. Both plasma ALA and EPA PUFA levels were increased two-fold (p<0.05) while consuming Salba.

Conclusions:Long-term supplementation with Salba attenuated a major cardiovascular risk factor (SBP) and emerging factors (hs-CRP and vWF) safely beyond conventional therapy, while maintaining good glycemic and lipid control in people with well-controlled type 2 diabetes.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.